Changes in Hong Kong stocks | McPharmaceutical-B (02335) rose more than 28% and obtained the MT200605 Phase III Clinical Trial Team Leader's Ethical Approval

The Zhitong Finance App learned that McPharmaceutical-B (02335) rose by more than 28%. As of press release, it had risen 18.8% to HK$19.32, with a turnover of HK$146 million.

According to the news, on the evening of November 4, Maike Pharmaceutical-B announced that the company and Beijing Tiantan Hospital (Beijing Tiantan Hospital) affiliated to Capital Medical University jointly undertook a research project involving the company's key product MT200605 under the “Major New Drug Creation” national science and technology project, and has recently received the first special funding from the central financial administration for this project.

The Group is responsible for the R&D, production and clinical trial supply of MT200605 as agreed in the project task book and the cooperation agreement between the two parties. After the completion of the MT200605 phase II clinical trial, the company has received the first special funding from the central government for this project and is promoting clinical development of MT200605 to phase III. The company recently obtained approval from the ethics committee of the MT200605 phase III clinical trial (phase III clinical trial) team leader unit (Beijing Tiantan Hospital) for treating patients with acute ischemic stroke.